Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study-Reference-Cited by-同舟云学术

Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study

Published:2021-01-18 Issue:2 Volume:32 Page:164-173
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Bruin-Weller Marjolein de¹^ORCID,Pink Andrew E.²,Patrizi Annalisa³,Gimenez-Arnau Ana M.⁴^ORCID,Agner Tove⁵,Roquet-Gravy Pierre-Paul⁶,Ferrucci Silvia M.⁷,Arenberger Petr⁸,Svensson Ake⁹,Schuttelaar Marie L.A¹⁰,Nosbaum Audrey¹¹,Jayawardena Shyamalie¹²,Rizova Elena¹³,Ardeleanu Marius¹⁴,Eckert Laurent¹⁵,Ozturk Zafer E.¹³

Affiliation:

1. National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, Netherlands

2. St. John’s Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK

3. Department of Dermatology, IRCCS Policlinico di S. Orsola, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy

4. Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain

5. Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

6. Department of Dermatology, Grand Hôpital de Charleroi, Charleroi, Belgium

7. Department of Dermatology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

8. Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic

9. Skåne University Hospital, Malmo, Sweden

10. Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

11. Allergy and Clinical Immunology Department, University of Lyon, Lyon Sud University Hospital, Pierre Benite, France

12. Sanofi, Bridgewater, NJ, USA

13. Sanofi Genzyme, Cambridge, MA, USA

14. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

15. Sanofi, Chilly-Mazarin, France

Funder

Sanofi and Regeneron Pharmaceuticals, Inc

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2020.1866741

Reference52 articles.

1. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults

2. Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases

3. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders

4. Null Mutations in the Filaggrin Gene (FLG) Determine Major Susceptibility to Early-Onset Atopic Dermatitis that Persists into Adulthood

5. Comparison of Skin Hydration Evaluation Sites and Correlations among Skin Hydration, Transepidermal Water Loss, SCORAD Index, Nottingham Eczema Severity Score, and Quality of Life in Patients with Atopic Dermatitis

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful therapy of Tuomin-Shizhen-Decoction in an adult patient with atopic dermatitis-A case report;Allergy Medicine;2024-08

2. Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks;Dermatology and Therapy;2024-07-13

3. Prevalence and coexistence of type 2 inflammatory diseases;Clinical and Translational Allergy;2024-06

4. Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom;Dermatology and Therapy;2024-04-23

5. Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study;Advances in Therapy;2023-10-06